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Background. Surgical treatment is the cornerstone in the management of colorectal cancer (CRC) liver metastases. The aim of this
study is to identify clinicopathological factors affecting disease-free (DFS) and overall survival (OS) in patients undergoing
potentially curative liver resection for CRC metastasis. Methods. All consecutive patients undergoing liver resection for first
recurrence of CRC from February 2006 to February 2018 were included. Prognostic impact of factors related to the patient,
primary and metastatic tumors, was retrospectively tested through univariate and multivariate analyses. Results. Seventy patients
were included in the study. Median postoperative follow-up was 37 months (range 1–119). Median DFS and OS were 15.2 and
62.7 months, and 5-year DFS and OS rates were 16% and 53%. In univariate analysis, timing of metastasis presentation/
treatment (combined colorectal and liver resection, “bowel first” approach or metachronous presentation) (p < 0 0001), ASA
score (p = 0 003), chemotherapy after liver surgery (p = 0 028), T stage (p = 0 021), number of resected liver lesions (p < 0 0001),
and liver margin status (p = 0 032) was significantly associated with DFS while peritoneal resection at colorectal surgery
(p = 0 026), ASA score (p = 0 036), extension of liver resection (p = 0 024), chemotherapy after liver surgery (p = 0 047),
and positive nodes (p = 0 018) with OS. In multivariate analysis, timing of metastasis presentation/treatment, ASA score, and
chemotherapy (before and after liver surgery) resulted significantly associated with DFS and timing of metastasis presentation/
treatment, positive nodes, peritoneal resection at colorectal surgery, and surgical approach (open or minimally invasive) of
colorectal resection with OS. Conclusions. Surgery may provide good DFS and OS rates for CRC liver metastasis. Patient
selection for surgery and correct timing of intervention within a multidisciplinary approach may be improved by taking into
account negative prognostic factors which stress the importance of systemic therapy.
1. Introduction
Colorectal cancer (CRC) is the third leading cause of cancer-
related death in developed countries [1]. The liver is the
commonest site of distant spread of CRC, and liver metas-
tases occur in up to 60% of those patients [2, 3].
Surgical treatment is the cornerstone of management of
CRC, apart from staging. Nevertheless, some authors believe
in a promoting effects of surgery on tumor spread stating that
manipulation of the tumor and its vessels may promote
tumor spillage, production of growth factors, and reduction
of the release of antiangiogenic factors [4, 5]. On the con-
trary, other authors suggest that removal of at least great
majority of tumor burden may reduce proinflammatory
effects and the release of circulating malignant cell leading
to a better control of metastasizing cells from host immunity
[6, 7]. Due to the technical and technological improvements
in liver surgery and perioperative care, hepatic resection has
become at least a part of the standard of care in metastatic
CRC. Indications to liver resection have been widened along
the past 3 decades maintaining acceptable morbidity and
mortality rates [8]. Nowadays, patients are considered
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suitable for surgery if all the disease can be resected with neg-
ative margins and preserving an adequate liver remnant [9,
10]. Unfortunately, only about 25% of the patients affected
meets these criteria [3]. Moreover, a multimodality and mul-
tidisciplinary evaluation and treatment, when appropriate, is
of paramount importance in this selected group of metastatic
patients in order to provide the best chances of cure [11, 12].
In patients fit for surgery, resection may provide 5-year
survival rates of 40–74% [9, 11, 12], 10-year survival rates
of 16–23%, and a cure rate of 20% [10] compared to a 5-
year survival rate of about 5% in case of palliative treatments
[3]. On the other hand, recurrence rate is reported to be high
(60–80%) with a 10–15% of early recurrence and disease-
specific deaths [8].
In order to help in the selection of the more appropriate
treatment, some prognostic factors in patients suffering from
CRC and metastatic CRC have been identified [2, 3, 8, 10].
The aim of this study is to verify and analyze different factors
which may affect disease-free survival (DFS) and overall
survival (OS). They are either related to the patient, to the
primitive CRC, or liver metastasis in the selected group of
patients who underwent liver resection for first and isolated
recurrence of colorectal cancer. Its perspective is the identifi-
cation of the subgroups of patients who could benefit more
from surgical resection in order to improve patient selection
and the choice of adequate timing for liver resection within a
multimodality treatment.
2. Materials and Methods
2.1. Study Design and Patients. From February 2006 to
February 2018, all the patients affected by “liver only” first
metastasization from CRC who underwent potentially cura-
tive surgical resection at the Hepatobiliary Surgery Unit of
Careggi Teaching Hospital were included in the study.
Patients undergoing intraoperative radiofrequency ablation
(RFA) with a curative intent were also included. Patients with
a primary rectal squamocellular carcinoma were excluded.
Preoperativeworkup included triple phase-contrast enhanced
computed tomography (CT) scan and pancolonoscopy. Liver
volume assessment was performed when indicated. Magnetic
resonance and positron emission tomography (PET) scan
were used to rule out doubtful cases. Intraoperative ultra-
sound sonography (IOUS) was routinely used during liver
surgery. Follow-up was done according to a standardized
scheduled program including CT scan or abdominal ultra-
sound, colonoscopy, and blood test examination. It could be
modified according to oncologist’s indications. Retrieval of
follow-up data was completed including the revision of any
available medical records and phone call interviews.
Day of liver surgery was chosen as reference date.
Disease-free interval was considered as the time between liver
surgery and the diagnosis of any site of recurrence of disease
or until the date of death while overall survival was consid-
ered as time between the liver surgery and the date of death
or the last visit for alive patients. Recurrences were treated
with surgery, chemotherapy, radiotherapy, percutaneous
treatment, combinations of them, or best supportive care
as appropriate.
According to timing of metastasis presentation/treat-
ment, patients were divided into 3 groups: “synchronous
combined surgery” that included patients who underwent
combined surgery for primary tumor and liver metastasis,
“synchronous bowel first” that included patients with
metastatic disease from the beginning of their neoplastic his-
tory but liver metastases were not treated during colorectal
surgery, and “metachronous” that included patients who
developed liver metastasis after colorectal cancer surgery.
The decision to perform combined or delayed surgery in syn-
chronous presentation with or without any perioperative
chemotherapy was discussed during Hospital Tumor Board
meetings. Patient’s conditions (i.e., comorbidities, bowel
obstruction) and wishes, number, dimension, and position
of the liver metastases at preoperative examination (con-
firmed or not at surgery time) were taken into account. Right
colon comprehended lesions located from the cecum to
transverse; left colon included also lesions located in the rec-
tum. In univariate analysis, converted procedures were
grouped with open surgery because this study is not an
“intention-to-treat” analysis. Peritoneal resection was defined
as any resection of the anterior aspect of the peritoneum
macroscopically adherent/infiltrated by the primary tumor.
Major hepatectomies were defined as resection of at least 3
segments according to Brisbane’s classification [13]. Postop-
erative complications occurred after hepatic resections were
evaluated if classified as at least grade 3 or 4 according to
Clavien-Dindo classification [14]. Chemotherapy before
and after liver surgery was considered if administered to
the patient despite the interruption of the initially scheduled
program. The lesion size (maximum diameter for both
primary and metastatic tumors) and number of hepatic
metastases resected were retrieved from histopathological
response. T stage was classified according to American
Joint Committee on Cancer (AJCC) TNM staging system,
7th edition definition [15]. Positive liver margins were
defined in presence of neoplastic cells within the surface
of resected liver.
2.2. Analysis. Patients’ data were prospectively collected into
a database which was retrospectively reviewed. Continuous
variables were reported as median and range while categori-
cal variables were reported as frequency and percentage.
Differences between the three groups were analyzed using
the Kruskal-Wallis test for continuous variables, while cate-
gorical variables were compared using the χ2 or Fisher exact
test when appropriated. Statistical significance was defined as
p value≤ 0.05.
For univariate analysis, estimate of DFS and OS rates was
calculated according to the Kaplan-Meier methods and
compared using log-rank test. Hazard ratios (HR) and their
95% confidence intervals (CI) were calculated by means of
the Cox proportional hazard model. The multivariate Cox
regression model was used to evaluate the independent effect
on DFS and OS of any factors whose p value was ≤0.15 at the
univariate analysis. Parameters related to the histopathologi-
cal response on liver specimens (i.e., number of resected
lesions, maximum diameter, and liver margin status) were
not considered in multivariate analysis because of their
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unavailability in the 7 patients who underwent intraoperative
curative RFA alone in order to avoid their exclusion from
this analysis.
Data were analyzed using the statistical software SAS
version 9.2 (SAS Corporation, Cary, NC).
3. Results and Discussion
3.1. Results
3.1.1. Patient Characteristics. Overall, 70 patients were
included in the study. Median follow-up was 37 months
(range 1–119). In particular, median follow-up among
survivors was 48 months (range 2–116). Analyzed patient
characteristics are displayed in Table 1. Patients undergo-
ing combined surgery were 25, a two-step surgery was
performed in 14 patients, and metachronous presentation
of metastases was seen in 31 patients. Age, sex, and pri-
mary tumor distribution were similar within these three
groups. Chemotherapy before liver surgery was adminis-
tered in a very low percentage (8%) of “combined surgery”
group (p < 0 0001).
Perioperative results are shown in Table 2. Open surgery
technique (p = 0 006) and minor/parenchymal-sparing liver
Table 1: Patients’ characteristics.
Synchronous
combined surgery
(n = 25) (35.7%)
Synchronous
“bowel first”
(n = 14) (20%)
Metachronous
(n = 31) (44.3%)
Total
(n = 70) p value
Age (years, range) 68 (34–85) 75 (46–82) 70 (52–85) 69.5 (34–85) 0.730
Sex (n, %) 0.683
Male 15 (60%) 9 (64.3%) 16 (51.6%) 40 (57.1%)
Female 10 (40%) 5 (35.7%) 15 (48.4%) 30 (42.9%)
Bowel obstruction (n, %) 5 (20%) 7 (50%) 7 (22.6%) 19 (27.1%) 0.097
Site of primary tumor (n, %) 0.343
Right colon 8 (32%) 2 (14.3%) 11 (35.5%) 21 (30%)
Left colon 17 (68%) 12 (85.7%) 20 (64.5%) 49 (70%)
CHT before liver surgery 2 (8%) 11 (78.6%) 20 (64.5%) 33 (47%) <0.0001
CHT= chemotherapy.
Table 2: Perioperative results.
Synchronous
combined surgery
(n = 25) (35.7%)
Synchronous
“bowel first”
(n = 14) (20%)
Metachronous
(n = 31) (44.3%)
Total
(n = 70) p value
Colorectal surgery
Technique (n, %) 0.006
Open 15 (60%) 5 (35.7%) 7 (22.6%) 40 (57.1%)
Minimally invasive 5 (20%) 9 (64.3%) 17 (54.8%) 31 (44.3%)
Converted 5 (20%) 0 7 (22.6%) 12 (17.1%)
Peritoneal resection (n, %) 2 (8%) 1 (7.1%) 2 (6.4%) 5 (7.1%) 1.00
Liver surgery
ASA (n, %) 0.522
1 3 (12%) 1 (7.1%) 2 (6.4%) 6 (8.6%)
2 7 (28%) 4 (28.6%) 11 (35.5%) 22 (31.4%)
3 11 (44%) 6 (42.9%) 17 (54.8%) 34 (48.6%)
4 4 (16%) 3 (21.4%) 1 (3.2) 8 (11.4)
Type of surgery (n, %) 0.024
Minor/wedge 22 (88%) 7 (50%) 17 (54.8%) 46 (65.7%)
Major 3 (12%) 4 (28.6%) 10 (32.3%) 17 (24.3%)
RFA 0 3 (21.4%) 4 (12.9%) 7 (10%)
Surgery duration (min, range) 300 (170–145) 242.5 (175–369) 230 (50–315) 255 (50–450) <0.0001
Complications (CD III-IV) (n, %) 3 (12%) 3 (21.4%) 4 (12.9%) 10 (14.3%) 0.743
CHT after liver surgery (n, %) 18 (72%) 4 (28.6%) 17 (54.8%) 39 (55.7%) 0.032
ASA =American Society of Anesthesiologists; Minor/wedge =minor hepatectomies/hepatic wedge resections; Major =major hepatectomies;
RFA = radiofrequency ablation; CD III-IV = Clavien-Dindo classification grade III-IV; CHT= chemotherapy.
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resection (p = 0 024) were more frequently applied in “com-
bined surgery” group. ASA score and postoperative compli-
cation distribution in the 3 groups were similar with an
overall median rate of severe complications after liver
surgery of 14.3%. A statistically significant difference in the
3 groups was found for the administration of chemotherapy
after liver surgery (p = 0 032) with the lowest percentage
(28.6%) in “bowel first” group.
Analyzed histopathological results are shown in Table 3.
T4 stage (p = 0 065) and bigger primary tumors (p = 0 024)
were more frequently (p = 0 065) found in “bowel first”
group. Lower median number (p = 0 334) and smaller size
of liver metastases were reported in “combined surgery”
group specimens (24mm versus 35mm in the other 2
groups, p = 0 005). Higher frequency of positive liver mar-
gins (p = 0 015) was found in “bowel first” group. Tumor
grading was not evaluated since almost all the patients
presented a G2 primary tumor. KRAS or BRAF evaluation
was not available in 55.7% of the patients; consequently, this
variable was not analyzed. However, 24 patients had a RAS
wild-type while 15 patients presented a RAS mutation.
3.1.2. Factors Associated with Disease-Free Survival (DFS)
and Overall Survival (OS). Recurrence after liver surgery
was documented in 46 patients (66%). Early recurrence
(within 6 months) occurred in 15 patients (21.4%), recur-
rence rate within the first year was 37% (26 patients), and
no other recurrences were found after the third year from
liver surgery. Median time between recurrence and death
was 29 months (range 1–89 months). Ninety-day mortality
was 1.4%.
Overall, 1-, 3-, and 5-year DFS rates were 59%, 17%, and
16%, respectively, with a median DFS rate of 15.2 months
(95% CI 11.2–21.5). Overall, 1-, 3-, and 5-year OS rates were
94%, 68%, and 53%, respectively, with a median OS rate of
62.7 months (95% CI 43.7–67.8).
Results of univariate analysis of factors associated with
DFS and OS are shown in Table 4.
Disease presentation and treatment timing (Figure 1)
significantly affected DFS (p < 0 0001) but not OS (p =
0 085). Metachronous group had a median DFS of 23.5
months compared to 14.4 months of DFS for “combined sur-
gery” group and 6 months for “bowel first” group. Compared
to “combined surgery group”, “bowel first” group had an HR
of 3.9 (95% HR CI 1.8–8.2) for DFS.
Surgical approach for colorectal surgery (Figure 2)
resulted marginally significant for OS (p = 0 058). Compared
to open and converted surgery, minimally invasive tech-
niques had anHR of 0.5 (95%HRCI 0.2–1) for OS. Peritoneal
resection at colorectal surgery was a negative significant
factor for OS (p = 0 026) but not for DFS (p = 0 414).
ASA score (Figure 3) was significantly associated with
both DFS (p = 0 003) and OS (p = 0 036). Three-year DFS
and OS rates for ASA score 1-2 were 38% and 79%, respec-
tively, compared with 6% and 67%, respectively, for ASA
score 3 and 0% and 38%, respectively, for ASA score 4.
Extension of hepatic resection (Figure 4) resulted associ-
ated with OS (p = 0 024) and approached statistical signifi-
cance in DFS (p = 0 060). Patients treated with RF had the
worst DFS with 1-year DFS rate of 29% and an HR 2.5
(95% HR CI 1.1–5.7) for DFS if compared to patients treated
with wedge/minor hepatic resection. Anyway, 1-year OS for
patients treated with RF was 100%. Compared to minor/
wedge resections, major hepatectomies had an HR 2.3 (95%
HR CI 1.2–4.5) for OS.
Administration of chemotherapy after liver surgery
(Figure 5) resulted positively associated with DFS (p = 0 028)
and OS (0.047). Median time between liver surgery and start
of chemotherapy treatment was 6.5 weeks (range 2.1–14.1).
T stage (Figure 6) was found to be a prognostic factor for
DFS (p = 0 002). T3 stage had an HR 0.65 (95% HR CI 0.3–
1.3) for DFS when compared to T1 and 2 stages. Number
Table 3: Histopathological results.
Synchronous
combined surgery
(n = 25) (35.7%)
Synchronous
“bowel first”
(n = 14) (20%)
Metachronous
(n = 31) (44.3%)
Total
(n = 70) p value
Colorectal specimen
Size (mm, range) 35 (17–130) 54 (25–90) 35 (4–82) 40 (4–130) 0.024
T stage∗ (n, %) 0.065
1-2 2 (8%) 4 (28.6%) 5 (16.1%) 11 (15.7%)
3 22 (88%) 8 (57.1%) 26 (83.9%) 56 (80%)
4 1 (4%) 2 (14.3%) 0 3 (4.3%)
Nodes harvested (n, range) 17 (7–76) 25 (6–48) 26 (9–50) 22 (6–76)
Positive nodes (n, range) 2 (0–10) 3.5 (0–17) 1 (0–12) 2 (0–17) 0.217
Mucinous histotype 3 (12%) 1 (7.1%) 9 (29%) 13 (18.6%) 0.159
Liver specimen n = 25 n = 11 n = 27 n = 63
Resected lesions (n, range) 1 (1–11) 2 (1–6) 1 (1–4) 1 (1–11) 0.334
Size (mm, range) 24 (4–50) 35 (15–80) 35 (12–110) 30 (4–110) 0.005
Positive margins (n, %) 0 3 (27.3%) 1 (3.7%) 4 (6.35) 0.015
∗T stage according to TNM definition AJCC 7th edition.
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Synchronous combined 25 52 24 20 14.4 (7.2–27.8) 92 66 48 45.3 (31–NE)
Synchronous “bowel first” 14 16 0 0 6 (2–11.4) 84 45 22 23.6 (11.8–70.9)
Metachronous 31 83 19 19 23.5 (14–28.8) 100 78 67 65.7 (58.2–77.2)
Age 0.648 0.552
<65 21 57 14 14 15.2 (7.2–22.1) 100 69 69 67.5 (23.6–77.9)
≥65 49 59 19 16 16.2 (10.4–23.5) 91 68 46 53 (37.9–65.7)
Sex 0.574 0.929
Male 40 59 14 11 16.4 (8.9–21.7) 95 75 57 64.2 (44.4–NE)
Female 30 58 22 22 14 (8.3–23.7) 93 58 49 38.1 (27.1–119.3)
Bowel obstruction 0.860 0.985
No 51 59 17 15 16.4 (10.4–21.7) 92 69 52 62.6 (43.7–70.9)
Yes 19 56 17 0 12.7 (4.2–28.7) 100 64 57 65.7 (21.7–119.3)
Site of primary tumor 0.488 0.661
Right colon 21 60 20 20 16.2 (8.5–29.4) 90 53 41 37.9 (17.1–77.2)
Left colon 49 58 16 13 15.2 (9.4–19.2) 96 74 60 64.7 (44.4–67.8)
CHT before liver surgery 0.080 0.531
No 37 62 23 20 19.2 (8.5–28.7) 92 71 52 62.6 (37.9–77.2)
Yes 33 54 10 10 12.7 (9.4–18) 97 63 58 62.7 (31.1–70.9)
Colorectal surgery
Technique 0.885 0.058
Open and converted 39 60 15 15 16.2 (8.9–24.8) 92 61 44 45.3 (31.3–67.1)
Minimally invasive 31 57 20 16 15.2 (8.3–23.5) 97 78 72 NE (43.7–NE)
Peritoneal resection 0.414 0.026
No 65 60 17 15 16.4 (11.8–21.7) 97 72 56 62.7 (44.3–67.8)
Yes 5 40 20 20 3.3 (1.3–NE) 60 20 20 12.4 (1.3–NE)
Liver surgery
ASA 0.003 0.036
1-2 28 73 38 33 21.5 (12.4–67.8) 92 79 62 67.8 (45.3–NE)
3 34 52 6 6 12.6 (7.2–22.4) 97 67 54 62.6 (32–67.1)
4 8 38 0 0 10.9 (1.3–19.2) 88 38 25 20.5 (1.3–NE)
Type of surgery 0.060 0.024
Minor/wedge 46 59 22 19 18 (10.4–27.8) 93 69 57 65.7 (43.7–NE)
Major 17 69 13 13 14 (6–21.5) 94 54 34 37.9 (14–62.7)
RFA 7 29 0 0 5 (1.5–18) 100 86 86 62.6 (12.4–119.3)
Surgery duration 0.999 0.945
<255min 34 67 13 13 18 (12–25) 94 71 55 64.7 (38.1–67.8)
≥255min 36 51 21 18 12.4 (8.5–21.7) 94 65 51 62.6 (31.1–70.9)
Complications (CD III-IV) 0.441 0.721
No 60 59 18 16 16.2 (10.4–22.1) 95 68 53 62.6 (38.1–67.5)
Yes 10 58 12 12 12.6 (1.3–30.9) 89 67 53 77.2 (9.2–77.2)
CHT after liver surgery 0.028 0.047
No 31 48 14 9 12 (5–18.1) 90 61 43 53 (19.2–70.9)
Yes 39 67 20 20 18 (11.8–27.8) 97 72 50 67.1 (44.4–70.9)
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of positive nodes (Figure 7) was significantly associated with
OS (p = 0 018). In case of no positive nodes, 3-year OS rate
was 86% compared to 83% with 1–3 positive nodes and
37% with at least 4 positive nodes.
Number of liver resected lesions (Figure 8) significantly
affected DFS (p < 0 0001). For OS, a statistically significant
difference was approached (p = 0 066). Patients with a single
liver metastasis had a 3-year DFS rate of 26% compared to
16% and 0% for patients with 2-3 or 4 or more lesions,
respectively. Patients with 4 or more liver lesions had a HR
7.4 (95% HR CI 3–18.4) for DFS when compared to patients
with only one liver lesion. Positive liver margins (Figure 9)
significatively affected DFS (p = 0 032). Patients with positive
liver margin had an HR 3.5 (95% HR CI 1–11.6) for DFS if
compared to the other patients.
Results of multivariate analysis for DFS and OS are
displayed in Tables 5 and 6, respectively. Metachronous
presentation, lower ASA score, and administration of che-
motherapy (both before and after liver surgery) resulted sig-
nificantly associated with a longer DFS. Synchronous
presentation treated with combined surgery, absence of pos-
itive nodes, no peritoneal resection during colorectal surgery,
and minimally invasive techniques used to perform colorec-
tal resection were found to be significantly associated with
longer OS.
3.2. Discussion. Several prognostic factors for DFS and OS in
patients affected by liver metastasis from CRC have been
found in this study. Although score systems considering
different prognostic factors for CRC already exist [10], this
study was conceived to investigate the role of potential prog-
nostic factors related to the patients and either to primary
tumor and liver metastasis in a restricted and recently treated
























≤33mm 26 60 8 8 18 (8.9–21.7) 100 79 57 62.7 (45.3–70.9)
34–49mm 20 69 24 16 23.5 (7.3–29.4) 95 72 64 65.7 (32–119.3)
≥50mm 24 48 22 22 11.8 (6–15.2) 87 51 40 37.9 (12.6–67.8)
T stage 0.002 0.347
1-2 11 51 10 10 12.4 (5–21.6) 90 68 28 53 (6–77.2)
3 56 62 19 17 16.6 (11.8–23.5) 96 68 59 64.7 (43.7–67.7)
4 3 0 0 0 3 (2–3.3) 50 50 50 40 (9.2–70.9)
Positive nodes 0.098 0.018
0 25 75 21 21 20.3 (12.4–28.8) 96 86 65 67 (53–119.3)
1–3 21 54 21 16 14.4 (5.8–28.7) 100 83 64 64.7 (37.9–70.9)
4+ 24 46 10 10 10.4 (3.6–16.6) 87 37 31 21.7 (14–77.2)
Mucinous histotype 0.940 0.286
No 57 58 17 15 58.2 (38–67) 96 68 50
Yes 13 60 17 17 (9–119.3) 84 67 67
Liver specimen
Resected lesions 0.0001 0.066
1 35 73 26 22 21.6 (15.2–28.7) 91 74 56 64.7 (43.7–77.2)
2-3 20 63 16 16 14.4 (7.3–23.5) 95 60 54 62.7 (21.7–NE)
4+ 8 13 0 0 5.7 (1.9–8.5) 100 43 14 27.1 (13.9–38.1)
Size 0.199 0.088
I tertile 20 55 20 15 17.2 (8.5–25) 90 73 50 60.4 (31.3–67.5)
II tertile 22 73 25 25 22.5 (12–28.8) 95 75 60 NE (32–NE)
III tertile 21 57 11 11 12.6 (5–24.8) 94 45 39 31.5 (14–70.9)
Margin status 0.032 0.859
Negative 59 63 20 18 16.5 (12–23.5) 100 66 50 58.2 (37.9–67.5)
Positive 4 38 0 0 4.8 (2–15.2) 93 50 50 47.2 (23.6–70.1)
NE = not evaluable; CHT = chemotherapy; ASA =American Society of Anesthesiologists; Minor/wedge =minor hepatectomies/hepatic wedge resections;
Major =major hepatectomies; RFA = radiofreqency ablation; CD III-IV = Clavien-Dindo classification grade III-IV. T stage according to TNM definition
AJCC 7th edition.
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of patients suffering from liver metastasis as first recurrence
of disease and undergoing potentially curative resection of
liver metastases.
Time of metastatic presentation was a significant prog-
nostic factor in both uni- and multivariate analyses. Patients
with synchronous presentation treated with a two-step
surgery had the worst prognosis. This group of patients was
older, more frequently presenting with bowel obstruction
and more comorbidities, with higher percentage of rectal
localization of the primary tumor (57% versus 12%) and big-
ger lesions (median maximum size of 54mm versus 35mm).
On the contrary, patients undergoing combined surgery
received more frequently a parenchymal-sparing operation
for smaller and for a median lower number of liver lesions.
Obviously, surgery time was significantly longer in “com-
bined surgery” group since surgery included also colorectal
resection. However, no negative effects were determined on
incidence of postoperative severe complications or on
prognosis. Correct timing of resection, especially in synchro-
nous presentation, and unequivocal criteria for surgery are
still under debate [3]. In a recently published English
population-based study, Vallance et al. [16] demonstrated
an increase in number of combined surgery performed along



















































Figure 1: Kaplan-Meier curve of disease-free survival (DFS) (p < 0 0001) and overall survival (OS) (p = 0 085) stratified by timing of
metastases presentation/treatment. Median DFS and OS for patients with synchronous presentation and combined surgery were
14.4months (95% CI 7.2–27.8) and 45.3 months (95% CI 31–not evaluable [NE]), respectively, versus 6 (95% CI 2–11.4) and 23.6months
(95% CI 11.8–70.9), respectively, for those with synchronous presentation treated with a two-step surgery versus 23.5 (95% CI 14–28.8)



















































Figure 2: Kaplan-Meier curve of disease-free survival (DFS) (p = 0 885) and overall survival (OS) (p = 0 058) stratified by technique used to
perform colorectal resection. Median DFS and OS for patients undergoing open and converted to open surgery techniques were 16.2months
(95% CI 8.9–24.8) and 45.3 months (95% CI 31.3–67.1), respectively, versus 15.2 (95% CI 8.3–23.5) and NE, respectively, for those
undergoing minimally invasive surgery. Open = open surgery approach and “converted to open surgery”; robot/LS =minimally invasive
approach including robotic and laparoscopic surgery; NE= not evaluable.
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tumor not located in the rectum and superficial and unilobar
metastases are the best conditions in which to perform a
combined surgery without increase in morbidity and mor-
tality rates [16, 17].
The site of primary tumor did not represent a significant
prognostic factor in this series. A slight better prognosis was
found for left-sided tumors. On the contrary, recent evi-
dences show a worse prognosis for right colon cancer
compared to left colon cancer and the relation between side
and genetic alterations, molecular profile, and, consequently,
response to chemotherapy [18, 19]. Prognostic relevance of
the primary tumor side with a more indolent biology of
left-sided cancer was also confirmed in the subgroup of
metastatic patients [20, 21]. In the present study, rectal
cancer that may have different prognosis was included within
left colon group. However, there are previous published
reports confirming a better prognosis for patients with liver
metastasis from left colon and rectal cancer considered
together [3, 22, 23]. Unfortunately, RAS and BRAF status





















































Figure 3: Kaplan-Meier curve of disease-free survival (DFS) (p = 0 003) and overall survival (OS) (p = 0 036) stratified by American Society of
Anesthesiologists (ASA) score. Median DFS and OS for patients with ASA score 1-2 were 21.5months (95% CI 12.4–67.8) and 67.8months
(95% CI 45.3–not evaluable [NE]), respectively, versus 12.6 (95% CI 7.2–22.4) and 62.6 months (95% CI 32–67.1), respectively, for those with





















































Figure 4: Kaplan-Meier curve of disease-free survival (DFS) (p = 0 060) and overall survival (OS) (p = 0 024) stratified by extension of
liver resection. Median DFS and OS for patients undergoing major hepatectomies were 14 months (95% CI 6–21.5) and 37.9months
(95% CI 14–62.7), respectively, versus 18 (95% CI 10.4–27.8) and 65.7 months (95% CI 43.7–NE), respectively, for those undergoing a
minor/wedge resections versus 5 (95% CI 1.5–18) and 62.6 months (95% CI 12.4–119.3), respectively, for patients treated with
radiofrequency ablation. Major =major hepatectomies; minor/wedge =minor hepatic resection/wedge resection; RF = radiofrequency
ablation; NE= not evaluable.
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(44.3%) precluding further analysis of this parameter. How-
ever, RAS mutation was documented in 15 patients and 10
of them had a left-sided tumor confirming the relevance of
molecular feature for the prognosis more than side of the
tumor itself.
Technique chosen to perform colorectal surgery was an
independent prognostic factor for OS (p = 0 007) on multi-
variate analysis. Advent of minimally invasive surgery was
followed by many reports demonstrating at least not inferior-
ity of these new techniques in oncological outcomes [24, 25].
Nevertheless, the well-known advantages in postoperative
outcomes of minimally invasive technique with reduction
of surgical stress and better preservation of immune system
[4], together with lower risk of incisional hernias and adhe-
sions, may explain this benefit in OS rate.
Peritoneal resection at colorectal resection resulted
strongly associated with OS rate in both univariate and mul-
tivariate analyses even though in the presence of wide 95%
confidence intervals. This is consistent with previous findings
that peritoneal wound seems to be predictive of the alter-
ations in the immune response more than skin incision [4].
Anyway, the small sample of patients who received a perito-






















































Figure 5: Kaplan-Meier curve of disease-free survival (DFS) (p = 0 028) and overall survival (OS) (p = 0 047) stratified by administration of
chemotherapy after liver surgery. Median DFS and OS for patients not receiving chemotherapy were 12 months (95% CI 5–18.1) and 53
months (95% CI 19.2–70.9), respectively, versus 18 (95% CI 11.8–27.8) and 67.1 months (95% CI 44.4–119.3), respectively, for those





















































Figure 6: Kaplan-Meier curve of disease-free survival (DFS) (p = 0 002) and overall survival (OS) (p = 0 347) stratified by T stage∗. Median
DFS and OS for T1-2 stages were 12.4 months (95% CI 5–21.6) and 53 months (95% CI 6–77.2), respectively, versus 16.6 (95% CI 11.8–23.5)
and 64.7 months (95% CI 43.7–67.7), respectively, for T3 stage versus 3 (95% CI 2–3.3) and 40 months (95% CI 9.2–70.9), respectively, T4
stage. ∗T stage of primary tumor classified according AJCC TNM staging system.
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ASA score resulted a prognostic factor for DFS in both
uni- and multivariate analyses and for OS in univariate
analysis. It seems quite obvious that patients in worst condi-
tions may have a worse response against the tumor and have
higher chance to die for any cause. Careful selection of
ASA 4 patients suitable for surgery is recommended.
In univariate analysis, extension of liver resection
approached statistical significance for DFS (p = 0 060)
and resulted significantly associated with OS (p = 0 024).
Radiofrequency ablation did not provide equivalent DFS
rates when compared to resections. However, beyond intrin-
sic technical limits, this treatment was used in selected and
fragile patients with smaller lesions that may be associated
with multiple micrometastasis explaining lower DFS rates
consistent with previous literature reports [26]. On the other
hand, lesions may be completely treated, and in case of recur-
rence, procedure may be repeated with a minimum impact
on the patients and on liver function explaining encouraging
OS rates. Patients undergoing minor hepatic resection or



















































Figure 7: Kaplan-Meier curve of disease-free survival (DFS) (p = 0 098) and overall survival (OS) (p = 0 018) stratified by positive nodes.
Median DFS and OS for patients without positive nodes were 20.3 months (95% CI 12.4–28.8) and 67 months (95% CI 53–119.3),
respectively, versus 14.4 (95% CI 5.8–28.7) and 64.7 months (95% CI 37.9–70.9), respectively, for those with 1 to 3 positive lymph nodes





















































Figure 8: Kaplan-Meier curve of disease-free survival (DFS) (p = 0 0001) and overall survival (OS) (p = 0 066) stratified by number of
resected metastatic lesions. Median DFS and OS for patients with 1 metastasis were 21.6 months (95% CI 15.2–28.7) and 64.7 months
(95% CI 43.7–77.2), respectively, versus 14.4 (95% CI 7.3–23.5) and 62.7 months (95% CI 21.7–NE), respectively, for those with 2 or 3
metastases versus 5.7 (95% CI 1.9–8.5) and 27.1 months (95% CI 13.9–38.1), respectively, for patients with 4 or more metastases.
NE= not evaluable.
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hepatectomies with a 5-year OS rate of 57% compared to
34%. Parenchymal-sparing operations are becoming the
standard of care for CRC liver metastasis even in light of
possible liver relapse of disease that may require redo surgery
with curative possibilities [27, 28]. Several papers reported
the advantages of this technique in terms of reduced postop-
erative morbidity and some survival benefit with adequate
oncological outcomes. In consideration of these results,
parenchymal-sparing surgery should be preferred, whenever
technically feasible [29, 30].
Chemotherapy before liver surgery resulted a negative
prognostic factor for DFS in multivariate analysis in the pres-
ent study. Vigano et al. [8] proposed to evaluate patient
response between end of chemotherapy and liver resection
as a “time test” and a prognostic factor suggesting the
possibility to exclude from surgery about a 15% of patients
who would present early recurrence. However, their findings
deserve further evaluations. On the contrary, in this series,
administration of chemotherapy after liver surgery resulted
a positive prognostic factor for DFS and OS in univariate
analysis and for DFS in multivariate analysis. Median time
between liver surgery and initiation of chemotherapy was
6.5 weeks (range 2.1–14.1). Obviously, there is a group of
patients who could be indicated for adjuvant treatments
because of the stage of disease, but they are not considered
fit for them. This is mostly related to older age and comorbid-
ities such as previous heart disease. All these factors may be
related to the worst OS rate more than chemotherapy itself,
coherently with multivariate analysis results. Previously pub-



















































Figure 9: Kaplan-Meier curve of disease-free survival (DFS) (p = 0 032) and overall survival (OS) (p = 0 859) stratified by liver margin status.
Median DFS and OS for patients with negative margins were 16.5 months (95% CI 12–23.5) and 58.2 months (95% CI 37.9–67.5),
respectively, versus 4.8 (95% CI 2–15.2) and 47.2 months (95% CI 23.6–70.1), respectively, for those having positive margins.
Table 5: Multivariate analysis of factors associated with disease-free survival.
p value HR HR and 95% CI
Timing of metastases presentation/treatment 0.0008
Synchronous “combined surgery” ref ref ref
Synchronous “bowel first” 0.219 1.9 0.7–5.5
Metachronous 0.067 0.5 0.2–1.1
ASA 0.005
1-2 ref ref ref
3 0.001 2.7 1.5–4.9
4 0.134 2.1 0.8–5.5
CHT before liver surgery 0.027
No ref ref ref
Yes 0.027 2.5 1.1–5.6
CHT after liver surgery 0.028
No ref ref ref
Yes 0.028 0.5 0.2–0.9
ref = reference; ASA =American Society of Anesthesiologists; CHT = chemotherapy.
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chemotherapy without an increase in OS [10, 31] confirming
also that elderly patients are often oncologically undertreated
[32]. Nevertheless, initiation of chemotherapy within 6–8
weeks is a recognized prognostic factor for OS [33, 34].
Unfortunately, the small sample of patients receiving chemo-
therapy after surgery in this series precluded a subgroup
analysis of the impact of the different chemotherapy regi-
mens and use of molecular targeted therapies.
T stage but not tumor size resulted a prognostic factor for
DFS on univariate analysis. While T4 stage resulted associ-
ated with very low DFS and OS rates after liver surgery, inter-
estingly, T3 stage had a better prognosis if compared to T1-2
stages. This may be related to the different administrations of
chemotherapy being T1-2 stages usually not indicated for
chemotherapy. This explanation is consistent with the results
of multivariate analysis in which chemotherapy but not T
stage resulted independent prognostic factor for DFS.
Positive nodes resulted significantly associated with OS in
uni- and multivariate analyses. These findings underline the
prognostic impact of AJCC TNM classification. Careful
selection for liver surgery in patients with a primary tumor
T4 stage or N2 is recommended.
Number of resected liver lesions was significantly associ-
ated with DFS. On the contrary, size of resected liver lesions
did not affect prognosis in this series. Interestingly, interme-
diate size of liver lesions showed better DFS rates when com-
pared with smaller or bigger lesions. A possible explanation
may be that in case of small lesions, presence of multifocal
undetectable micrometastases is possible while bigger lesions
are related to a huge burden of disease.
Liver margin status was an independent prognostic factor
for OS, accordingly to the prognostic importance of at least
submillimetric clear margin which has been previously
reported [35].
This study has some limitations. It is a retrospective study
with the inherent selection bias. It is a small series leading
to a careful and critical interpretation of some findings.
Nevertheless, because of the small sample available, some
variables analyzed were divided into subgroup that may
include patients with different prognosis related to that
variable (i.e., left colon including rectum or administration
of chemotherapy without distinction if a molecular targeted
therapy was added or not). A strength of this paper is that a
recent series of resected patients has been analyzed, but on
the other hand, follow-up period is quite short considering
the proposal of at least 10-year follow-up due to the possibil-
ity of late recurrence [10]. Furthermore, although follow-up
scheduled program was standardized, some patients may be
evaluated with a different timing and patient compliance
was not always complete. Consequently, date of recurrence
may be influenced.
4. Conclusions
In the treatment of liver metastases from CRC, several factors
were associated with at least marginal significance with either
DFS or OS. Synchronous presentation treated with combined
surgery and metachronous presentation, use of a minimally
invasive technique in colorectal surgery, no necessity to per-
form a peritoneal resection in colorectal surgery, minor/
wedge liver resection, administration of chemotherapy after
liver surgery, T1–3 stages, negative lymph nodes, single liver
lesions and negative liver margins were related with better
prognosis. Moreover, none of the analyzed factor was associ-
ated with a so bad prognosis to contraindicate surgery.
Multimodality and multidisciplinary treatment is of
paramount importance to achieve higher cure rates, and in
this light, DFS should be the most important parameter
to evaluate. Aggressive perioperative systemic treatment
may be required in the presence of negative prognostic
factors, whenever possible. Nevertheless, patient selection
remains challenging and further improvements in prog-
nostication are necessary to identify patients unlikely to
benefit from resection.
Table 6: Multivariate analysis of factors associated with overall survival.
p value HR HR and 95% CI
Timing of metastases presentation/treatment 0.053
Synchronous “combined surgery” ref ref ref
Synchronous “bowel first” surgery” 0.025 2.8 1.1–7
Metachronous 0.895 1.1 0.5–2.3
Positive nodes 0.008
0 ref ref ref
1–3 0.267 1.7 0.7–4.4
4+ 0.003 3.8 1.6–9.1
Peritoneal resection 0.0003
No ref ref ref
Yes 0.0003 12.1 3.1–46.7
Technique for colon resection 0.007
Open ref ref ref
Minimally invasive 0.007 0.3 0.1–0.7
ref = reference.
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